Erratum: Treating pulmonary hypertension post cardiopulmonary bypass in pigs: Milrinone vs. sildenafil analog (Perfusion (2008) 23 (117-125) DOI 10.1177/0267659108094739);Treating pulmonary hypertension post cardiopulmonary bypass in pigs: Milrinone vs. sildenafil analog

Perfusion

Volumn 23, Issue 2, 2008, Pages 117-125

  Urdaneta, F ^a,b   Lobato, E B ^a,b   Beaver, T ^a   Muehlschlegel, J D ^a   Kirby, D S ^b   Klodell, C ^a   Sidi, Avner ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary Bypass; Milrinone; Pulmonary Hypertension; Sildenafil

Indexed keywords

MILRINONE; SILDENAFIL; UK 343 664; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CLAMPING; ARTERY CATHETERIZATION; ARTICLE; CARDIOPULMONARY BYPASS; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DRUG EFFICACY; HEART OUTPUT; HEMODYNAMIC MONITORING; LOADING DRUG DOSE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SINUS RHYTHM; SWINE; SYSTEMIC VASCULAR RESISTANCE;

EID: 61549088402     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659111424110     Document Type: Erratum

References (44)

1. Tilney NL Hester WJ. Physiologic and histologic changes in the lungs of patients dying after prolonged cardiopulmonary bypass: An inquiry into the nature of post-perfusion lung. Ann Surg. 1967; 166: 759-766.
2. Wessel DL Adatia I Giglia TM Thompson JE Kulic TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary artery hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993; 88: 447-453.
3. Hopkins RA Bull C Haworth SG Leval MR Stark J. Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardio-thorac Surg 1991; 5: 628-634.
4. Wahlers TH Beer C Fieguth HG. et al. Right heart failure following orthotopic cardiac transplantation. Clin Transplant 1988; 2: 252-256.
5. Kaye MP. The registry of the International Society for Heart and Lung Transplantation: 10th official report-1993. J Heart Lung Transplant 1993; 12: 541-548.
6. Reich DL Bodian CA Krol M Kuroda M Osinski T Thys DM. Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. Anesth Analg. 1999; 89: 814-822.
7. Ocal A Kiris I Erdinc M Peker O Yavuz T Ibrisim E. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med 2005; 207: 51-58.
8. Fattouch K Sbraga F Sampognaro R. et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: A randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006; 7: 119-123.
9. Ibrahim M Hendry P Masters R. et al. Management of acute severe perioperative failure of cardiac allografts: A single-centre experience with a review of the literature. Can J Cardiol 2007; 23: 363-367.
10. Oztekin I Yazici S Oztekin DS Goksel O Issever H Canik S. Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension. Yakugaku Zasshi 2007; 127: 375-383.
11. Lowson SM Doctor A Walsh BK Doorley PA. Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med 2002; 30: 2762-2764.
12. Ichinose F Roberts JD Zapol W. Inhaled nitric oxide: A selective pulmonary vasodilator: Current uses and therapeutic potentials. Circulation 2004; 109: 3106-3111.
13. Fullerton DC Mc Intyre RC. Inhaled nitric oxide: Therapeutic applications in cardiothoracic surgery. Ann Thorac Surg 1996; 61: 1856-1864.
14. Schmid ER Burki C Engel MH Schmidlin D Tornic M Seifert B. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. Anesth Analg 1999; 89: 1108-1115.
15. McMullan DM Bekker JM Johengen MJ. et al. Inhaled nitric oxide-induced rebound pulmonary hypertension: Role for endothelin-1. Am J Physiol Heart Circ Physiol 2001; 280: H777-H785.
16. Bradford KK Deb B Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000; 36: 146-151.
17. Pascual JM Fiorelli AI Bellotti GM Stolf NA Jatene AD. Prostacyclin in the management of pulmonary hypertension after heart transplantation. J Heart Transplant 1990; 9: 644-651.
18. Van Obbergh LJ Charbonneau M Blaise G. Combination of inhaled nitric oxide with IV nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br J Anaesth 1996; 77: 227-231.
19. Tonz M von Segesser LK Schilling J. et al. Treatment of acute pulmonary hypertension with inhaled nitric oxide. Ann Thorac Surg 1994; 58: 1031-1035.
20. Dent G Magnussen H Rabe KF. Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994; 172: 129-146.
21. Chen EP Bittner HB Davis RD Van Trigt P. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant 1998; 17: 669-678.
22. Bhatia S Frantz RP Severson CJ Durst LA McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78: 1207-1213.
23. Schulze-Neick I Hartenstein P Li J. et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108(Suppl 1): II167-II173.
24. Bonnell M Urdaneta F Kirby DS Valdez N Beaver TM Lobato EB. Effects of a sildenafil analog UK343-664 on a porcine model of acute pulmonary hypertension. Ann Thorac Surg 2004; 77: 238-242.
25. Atz AM Wessel DL. Sildenafil ameliorates effect of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91: 307-310.
26. Mychaskiw G Sachdev V Heath BJ. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular device. J Clin Anesth 2001; 13: 218-220.
27. Weimann J Ullrich R Hromi J. et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92: 1702-1712.
28. Tanaka H Tajimi K Moritsune O Kobayashi K Okada K. Effects of milrinone on pulmonary vasculature in normal dogs and in dogs with pulmonary hypertension. Crit Care Med 1991; 19: 68-74.
29. Tanaka H Tajimi K Matsumoto A Kobayashi K. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: A comparison with those of dopamine and dobutamine. Clin Exp Pharmacol Physiol 1990; 17: 681-690.
30. Tsai BM Wang M Pitcher JM Kher A Crisostomo P Meldrum DR. Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock 2005; 24: 417-420.
31. Schermuly RT Krupnik E Tenor H. et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001; 164: 1694-1700.
32. Matot I Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 2004; 125: 644-651.
33. Carteaux JP Roux S Siaghy M. et al. Acute pulmonary hypertension after cardiopulmonary bypass in pig: The role of endogenous endothelin. Eur J Cardiothorac Surg 1999; 15: 346-352.
34. Trachte AL Lobato EB Urdaneta F. et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79: 194-197.
35. Ghofrani HA Voswinckel R Reichenberger F. et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-1496.
36. Lobato EB Beaver T Muehlschlegel J Kirby DS Klodell C Sidi A. Treatment with phosphodiesterase inhibitors type III and V: Milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth 2006; 96: 317-322.
37. Steiner MK Preston IR Klinger JR Hill NS. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005; 5: 245-250.
38. Russell PC Emery CJ Cai YN Barer GR Howard P. Enhanced reactivity to bradykinin, angiotensin I and the effect of captopril in the pulmonary vasculature of chronically hypoxic rats. Eur Respir J 1990; 3: 779-785.
39. Madden BP Sheth A Ho TB Park JE Kanagasabay RR. Potential role for sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgery. Br J Anaesth 2004; 93: 155-156.
40. Mikhail GW Prasad SK Li W. et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: Acute and mid-term effects. Eur Heart J 2004; 25: 431-436.
41. Rybalkin SD Yan C Bornfeldt KE Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93: 280-291.
42. Ockaili R Salloum F Hawkins J Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K (ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002; 283: H1263-H1269.
43. Kieler-Jensen N Milocco I Ricksten SE. Pulmonary vasodilation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant 1993; 12: 179-184.
44. Lowson SM. Inhaled alternatives to nitric oxide. Anesthesiology 2002; 96: 1504-1513.